截至本激励计划草案公告日，公司2022年、2023年、2024年股票期权激励计划尚在实施中，合计尚有 1,337.18万份仍在有效期内。公司全部有效期内的股权激励计划所涉及的标的股票总数累计未超过本激 励计划提交股东会审议时公司股本总额的20%。本激励计划中任何一名激励对象通过全部在有效期内的 股权激励计划获授的本公司股票数量累计不超过本计划提交股东会审议时公司股本总额的1.00%。 格隆汇1月20日丨普门科技(688389.SH)公布2026年股票期权激励计划，本激励计划拟向激励对象授予 1,689万份股票期权，约占本激励计划草案公告日公司股本总额的3.94%，不设置预留权益。激励对象获 授的每份股票期权在满足行权条件的情况下，拥有在有效期内以行权价格购买1股公司股票的权利。 ...

Core Viewpoint - Pumen Technology (688389.SH) has recently received a medical device registration certificate from the Guangdong Provincial Drug Administration for 17α-hydroxyprogesterone, a key C21 steroid hormone that plays an important role in steroid hormone synthesis pathways in the human body [1] Group 1: Product Details - 17α-hydroxyprogesterone (17α-OH P) is a crucial intermediate in the steroid hormone synthesis pathway, positioned at a branching point in the cortisol synthesis pathway as a precursor to 11-deoxycortisol and also as a precursor to androstenedione in the androgen synthesis pathway [1] - The product is intended for the quantitative measurement of 17α-hydroxyprogesterone levels in human serum, providing significant reference value for the diagnosis, disease progression, and therapeutic observation of adrenal cortex diseases [1] Group 2: Clinical Application - The clinical application of 17α-hydroxyprogesterone is primarily for the auxiliary diagnosis of adrenal cortex diseases, but it is not intended for the auxiliary diagnosis of congenital adrenal hyperplasia in newborns [1]

Core Viewpoint - Pumen Technology (688389.SH) announced a stock option incentive plan for 2026, proposing to grant 16.89 million stock options, which accounts for approximately 3.94% of the company's total share capital as of the announcement date [1] Group 1: Incentive Plan Details - The incentive plan does not set aside any reserved rights [1] - Each stock option granted allows the recipient to purchase one share of the company's stock at the exercise price, provided that the exercise conditions are met [1] - As of the announcement date, the company has ongoing stock option incentive plans for 2022, 2023, and 2024, with a total of 13.37 million options still valid [1] Group 2: Share Capital and Limits - The total number of shares involved in all valid stock incentive plans does not exceed 20% of the company's total share capital at the time of the plan's submission for shareholder approval [1] - Any individual recipient of the incentive plan will not receive more than 1.00% of the company's total share capital in stock options [1]

Core Viewpoint - The company has received a medical device registration certificate for the 17α-hydroxyprogesterone assay kit, which is significant for diagnosing adrenal cortex diseases [1] Group 1: Product Registration - The product is classified as a Class II medical device and has a validity period until January 18, 2031 [1] - The assay kit is used for the quantitative measurement of 17α-hydroxyprogesterone levels in human serum [1] Group 2: Market Impact - The acquisition of the registration certificate enhances the company's portfolio of electrochemiluminescence assay products, increasing its market competitiveness [1] - The actual sales performance of the product post-launch will depend on market promotion efforts, making the future impact on the company's performance uncertain [1] Group 3: Company Achievements - As of the announcement date, the company and its subsidiaries have obtained 109 medical device registration certificates for electrochemiluminescence assay kits [1]

Core Viewpoint - The company has received a medical device registration certificate for a specific product from the Guangdong Provincial Drug Administration [1] Group 1 - The product is a Sulfate Dehydroepiandrosterone Measurement Kit (Electrochemical Luminescence Method) [1]

Core Viewpoint - The company has received a medical device registration certificate for its DHEA-S testing kit, which is expected to enhance its competitiveness in the immunodiagnostics market [1] Group 1: Product Development - The DHEA-S testing kit is designed for the quantitative measurement of dehydroepiandrosterone sulfate (DHEA-S) levels in human serum or plasma [1] - The clinical application of the product is to evaluate the adrenal secretion of androgens [1] Group 2: Market Impact - The registration certificate from the Guangdong Provincial Drug Administration signifies that the product has obtained market access in China [1] - The actual sales performance of the product post-launch will depend on future marketing efforts, and its impact on the company's future performance remains uncertain [1]

深圳普门科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于近期收到了1个广东省 药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外诊断试剂）》， 具体情况如下： 二、对公司的影响 硫酸脱氢表雄酮（DHEA-S）是最丰富的肾上腺雄激素，也是一种由肾上腺 皮质产生的神经类固醇。作为肾上腺雄激素分泌的良好指标，DHEA-S 仅表现出 较弱的雄激素活性，但可以代谢为更活跃的雄激素，如睾酮和雄烯二酮。血清和 血浆 DHEA-S 的水平高于所有其他类固醇。男性和女性的 DHEA-S 水平在 30 岁 左右达到最高水平，之后随着年龄的增长而下降。DHEA-S 的半衰期较长，约为 8-10 小时，远长于半衰期约为 30-60 分钟的其他雄激素，且 DHEA-S 日变化有限， 是一种简便的评价肾上腺分泌激素的指标。 截至本公告披露日，公司及控股子公司已取得 108 个电化学发光配套检测试 剂注册证。上述产品注册证的获得，进一步丰富和完善 ...

Core Viewpoint - The company has received a medical device registration certificate for its DHEA-S testing kit, enhancing its competitive position in the immunodiagnostics market [1] Group 1: Product Development - The company has obtained the "Medical Device Registration Certificate" from the Guangdong Provincial Drug Administration for the DHEA-S testing kit, which is used for the quantitative measurement of DHEA-S levels in human serum or plasma [1] - The DHEA-S testing kit is clinically used to evaluate the level of androgen secretion from the adrenal glands, indicating its relevance in medical diagnostics [1] Group 2: Market Impact - The acquisition of the registration certificate enriches the company's portfolio of electrochemiluminescence reagent projects, potentially improving its market competitiveness in the immunodiagnostics field [1] - The actual sales performance of the product post-launch will depend on future marketing efforts, and the specific impact on the company's future performance remains unpredictable [1]

Group 1 - The core business of the company includes in vitro diagnostics, clinical medicine, skin aesthetics, and consumer health, and it does not involve brain engineering [2]

Core Viewpoint - The company has established a comprehensive incentive mechanism, utilizing a variety of methods to motivate core personnel and attract more talented individuals, with the stock option incentive plan being one of the diverse incentive methods [1] Summary by Relevant Sections - Stock Option Plans - The exercise price for the stock option incentive plan established in 2021 was set at 21.00 yuan per share, while the 2022 plan's exercise price was set at 20.00 yuan per share, both of which are higher than the company's current stock price [1] - The stock option incentive plans are based on a self-exercise model, allowing the incentive recipients to decide on exercising options based on the exercise price, stock price, and their own financial situation [1] - Incentive Mechanism - The company has developed a well-rounded incentive mechanism that includes various incentive methods to motivate key personnel and attract more outstanding talent [1]